secwatch.observer — SEC 8-K summary
======================================

Issuer:     CARGO Therapeutics, Inc. (—)
CIK:        0001966494
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001193125-25-056674
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CARGO suspends all pipeline development, cuts 90% of workforce, appoints interim CEO to pursue reverse merger
--------------------------------------------------------------------------------

- Board approves suspending CRG-023 and allogeneic platform; workforce reduced ~90%.
- Cash, cash equivalents and marketable securities total $368.1M as of Dec 31, 2024.
- Expected exit costs of $24M–$29M, majority recognized in H1 2025.
- CEO Gina Chapman departs May 19, 2025; CFO/COO Anup Radhakrishnan appointed interim CEO.
- Engaged TD Cowen as exclusive financial advisor to explore reverse merger or other strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1966494/000119312525056674/0001193125-25-056674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1966494/000119312525056674/d835509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-056674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer